Sign up for our FREE Pain E-Weekly for more coverage like this sent to your inbox!
The findings, first reported at the American Academy of Pain Medicine’s annual meeting, suggest that a unique microglial target can effectively treat the disorder, according to lead investigator Jarred Younger, PhD.
Despite the study’s promising data, the low-dose amount of naltrexone used on participants is not yet commercially available and must be compounded manually for patients.
Related Articles on Pain Management:
Florida Pain Network Adds Orlando Clinics to Expanded Database
Study: Risk of Perioperative Infection Lower in Patients With Chronic Opioid Consumption
Ameritox Supports New Recommendations for Long-Term Opioid Therapy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.